tirzepatide cardiovascular risk UC Irvine researchers project cardiac benefits from weight-loss medication Abstract 4361308: Tirzepatide Reduces the

SURMOUNT-1: the landmark obesity trial This 72-week, randomized, double-blind, placebo-controlled trial enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity

Right-sizing your packaging portfolio can turn a potential volume loss into a value win

Moulin, S

Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy

Every compounded semaglutide vial from Optimal Balance Pharmacy carries a Beyond Use Date (BUD) printed on the vial label per USP sterile compounding standards

Research shows it may influence nitric oxide signaling and cytokine activity